← Back to Search

Monoclonal Antibodies

NBE-002 for Breast Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by NBE-Therapeutics AG
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 60 months
Awards & highlights

Study Summary

This trial will study a new cancer drug to see if it is safe and effective.

Eligible Conditions
  • Solid Tumors
  • Cancer
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 60 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 60 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Anti-tumor Activity (Phase 2)
Recommended Phase 2 Dose (RP2D) (Phase 1)
Secondary outcome measures
Concentrations of NBE-002
Concentrations of NBE-002-reactive antibodies
Incidence of Adverse Events (Safety and Tolerability)
+1 more

Trial Design

4Treatment groups
Experimental Treatment
Group I: Safety-expansion Cohort (SEC)Experimental Treatment1 Intervention
Dose to be determined based on DEC.
Group II: Expansion Cohort 2 (EC2)Experimental Treatment1 Intervention
Dose to be determined based on DEC and SEC.
Group III: Expansion Cohort 1 (EC1)Experimental Treatment1 Intervention
Dose to be determined based on DEC and SEC.
Group IV: Dose-escalation Cohort (DEC)Experimental Treatment1 Intervention
Escalating doses of NBE-002 depending on cohort at enrollment.

Find a Location

Who is running the clinical trial?

NBE-Therapeutics AGLead Sponsor
Cmed Clinical ServicesOTHER
2 Previous Clinical Trials
165 Total Patients Enrolled

Media Library

NBE-002 (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT04441099 — Phase 1 & 2
Breast Cancer Research Study Groups: Expansion Cohort 2 (EC2), Dose-escalation Cohort (DEC), Safety-expansion Cohort (SEC), Expansion Cohort 1 (EC1)
Breast Cancer Clinical Trial 2023: NBE-002 Highlights & Side Effects. Trial Name: NCT04441099 — Phase 1 & 2
NBE-002 (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04441099 — Phase 1 & 2
~2 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top